These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2440073)
1. Serotonin uptake inhibition during treatment of depression with nortriptyline caused by parent drug and not by 10-hydroxymetabolites. Malmgren R; Aberg-Wistedt A; Bertilsson L Psychopharmacology (Berl); 1987; 92(2):169-72. PubMed ID: 2440073 [TBL] [Abstract][Full Text] [Related]
2. Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline. Nordin C; Bertilsson L; Siwers B Clin Pharmacol Ther; 1987 Jul; 42(1):10-9. PubMed ID: 2439250 [TBL] [Abstract][Full Text] [Related]
3. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Asberg M; Ringberger VA; Sjöqvist F; Thorén P; Träskman L; Tuck JR Clin Pharmacol Ther; 1977 Feb; 21(2):201-7. PubMed ID: 13959 [TBL] [Abstract][Full Text] [Related]
4. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline. Nordin C; Bertilsson L Clin Pharmacokinet; 1995 Jan; 28(1):26-40. PubMed ID: 7712660 [TBL] [Abstract][Full Text] [Related]
5. A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings. Aberg-Wistedt A; Ross SB; Jostell KG; Sjöquist B Acta Psychiatr Scand; 1982 Jul; 66(1):66-82. PubMed ID: 6181652 [TBL] [Abstract][Full Text] [Related]
6. Biochemical effects of antidepressant treatment--studies of monoamine metabolites in cerebrospinal fluid and platelet [3H]imipramine binding. Asberg M; Wägner A Ciba Found Symp; 1986; 123():57-83. PubMed ID: 2434288 [TBL] [Abstract][Full Text] [Related]
7. Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Mårtensson B; Wägner A; Beck O; Brodin K; Montero D; Asberg M Acta Psychiatr Scand; 1991 Feb; 83(2):125-33. PubMed ID: 1708190 [TBL] [Abstract][Full Text] [Related]
8. CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite. Nordin C; Bertilsson L; Siwers B Br J Clin Pharmacol; 1985 Oct; 20(4):411-3. PubMed ID: 4074608 [TBL] [Abstract][Full Text] [Related]
9. Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects. Asberg M Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):18-26. PubMed ID: 10583 [TBL] [Abstract][Full Text] [Related]
10. Treatment of depression with E-10-hydroxynortriptyline--a pilot study on biochemical effects and pharmacokinetics. Nordin C; Bertilsson L; Dahl ML; Resul B; Toresson G; Sjöqvist F Psychopharmacology (Berl); 1991; 103(3):287-90. PubMed ID: 2057534 [TBL] [Abstract][Full Text] [Related]
11. Alaproclate a novel antidepressant? A biochemical and clinical comparison with zimeldine. Aberg-Wistedt A; Alvariza M; Bertilsson L; Malmgren R; Wachtmeister H Acta Psychiatr Scand; 1985 Mar; 71(3):256-68. PubMed ID: 2580422 [TBL] [Abstract][Full Text] [Related]
12. Initial clinical trial based on biochemical methodology of zimelidine (a serotonin uptake inhibitor) in depressed patients. Siwers B; Ringberger VA; Tuck JR; Sjöqvist F Clin Pharmacol Ther; 1977 Feb; 21(2):194-200. PubMed ID: 837638 [TBL] [Abstract][Full Text] [Related]
13. Monoamine precursors, transmitters and metabolites in cerebrospinal fluid: a prospective study in healthy male subjects. Eklundh T; Eriksson M; Sjöberg S; Nordin C J Psychiatr Res; 1996; 30(3):201-8. PubMed ID: 8884658 [TBL] [Abstract][Full Text] [Related]
14. Biochemical effects of zimelidine in man. Bertilsson L; Tuck JR; Siwers B Eur J Clin Pharmacol; 1980 Nov; 18(6):483-7. PubMed ID: 6450684 [TBL] [Abstract][Full Text] [Related]
15. Concentration gradients of monoamine metabolites in human cerebrospinal fluid. Sjöström R; Ekstedt J; Anggård E J Neurol Neurosurg Psychiatry; 1975 Jul; 38(7):666-8. PubMed ID: 1159438 [TBL] [Abstract][Full Text] [Related]
16. Kinetics of drug-induced changes in dopamine and serotonin metabolite concentrations in the CSF of the rat. Mignot E; Laude D; Elghozi JL J Neurochem; 1984 Mar; 42(3):819-25. PubMed ID: 6198472 [TBL] [Abstract][Full Text] [Related]
17. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208 [TBL] [Abstract][Full Text] [Related]
18. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Mitani H; Shirayama Y; Yamada T; Kawahara R Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):531-4. PubMed ID: 16414168 [TBL] [Abstract][Full Text] [Related]
19. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid. Vaughn DM; Coleman E; Simpson ST; Satjawatcharaphong C Am J Vet Res; 1988 Aug; 49(8):1302-6. PubMed ID: 2459997 [TBL] [Abstract][Full Text] [Related]
20. 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. Stuerenburg HJ; Ganzer S; Müller-Thomsen T Neuro Endocrinol Lett; 2004 Dec; 25(6):435-7. PubMed ID: 15665806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]